|
rs506500
|
BHMT;DMGDH
|
Serum selenium measurement
|
|
0.800 |
GeneticVariation |
GWASDB |
Genome-wide association study identifies loci affecting blood copper, selenium and zinc.
|
23720494 |
2013 |
|
rs506500
|
BHMT;DMGDH
|
Serum selenium measurement
|
|
0.800 |
GeneticVariation |
GWASCAT |
Genome-wide association study identifies loci affecting blood copper, selenium and zinc.
|
23720494 |
2013 |
|
rs558133
|
BHMT;DMGDH
|
Selenium measurement
|
A |
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association study of selenium concentrations.
|
25343990 |
2015 |
|
rs567754
|
BHMT;DMGDH
|
Selenium measurement
|
T |
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association study of selenium concentrations.
|
25343990 |
2015 |
|
rs7700970
|
BHMT;DMGDH
|
Selenium measurement
|
T |
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association study of selenium concentrations.
|
25343990 |
2015 |
|
rs7700970
|
BHMT;DMGDH
|
Serum selenium measurement
|
T |
0.700 |
GeneticVariation |
GWASDB |
Genome-wide association study identifies loci affecting blood copper, selenium and zinc.
|
23720494 |
2013 |
|
rs3733890
|
BHMT;DMGDH
|
Hyperhomocysteinemia
|
|
0.030 |
GeneticVariation |
BEFREE |
Association between the BHMT gene rs3733890 polymorphism and the efficacy of oral folate therapy in patients with hyperhomocysteinemia.
|
31111486 |
2019 |
|
rs3733890
|
BHMT;DMGDH
|
Hyperhomocysteinemia
|
|
0.030 |
GeneticVariation |
BEFREE |
BHMT and BHMT_1 DNA methylation proportionally mediated the effects of rs3733890 SNPs on the efficacy of folate therapy for HHcy.
|
31826386 |
2019 |
|
rs3733890
|
BHMT;DMGDH
|
Hyperhomocysteinemia
|
|
0.030 |
GeneticVariation |
BEFREE |
Probands with rs1801394 "GG" genotype and BHMT rs3733890 "G" allele showed association with hyperhomocysteinemia.
|
29407547 |
2018 |
|
rs3733890
|
BHMT;DMGDH
|
Neural Tube Defects
|
|
0.030 |
GeneticVariation |
BEFREE |
The BHMT gene rs3733890, RFC1 gene rs1051266 and MTR gene rs1805087 were associated with the occurrence of NTDs in Han population of Northern China.
|
28770393 |
2018 |
|
rs3733890
|
BHMT;DMGDH
|
Neural Tube Defects
|
|
0.030 |
GeneticVariation |
BEFREE |
MTHM 501A>G only in case of GDM, and BHMT 716G>A only in case of no folate supplementation contribute to the etiology of NTDs.
|
24326202 |
2014 |
|
rs3733890
|
BHMT;DMGDH
|
Neural Tube Defects
|
|
0.030 |
GeneticVariation |
BEFREE |
Since genetic deficiencies in folate-dependent homocysteine metabolism have been identified in NTD families, we investigated a common variant in betaine-homocysteine methyltransferase (BHMT), 742G-->A (R239Q), as a genetic modifier of NTD risk.
|
12749058 |
2003 |
|
rs749710704
|
BHMT;DMGDH
|
Squamous cell carcinoma of the head and neck
|
|
0.020 |
GeneticVariation |
BEFREE |
We conducted a case-control study (265 HNSCC cases and 466 non-cancer controls) to investigate associations of MTHFR C677T and A1298C, MTR A2756G, MTRR A66G, RFC1 A80G, MTHFD1 G1958A, CBS 844ins68, TC2 C776G and A67G, SHMT C1420T and BHMT G742A polymorphisms with HNSCC risk.
|
22051736 |
2012 |
|
rs749710704
|
BHMT;DMGDH
|
Squamous cell carcinoma of the head and neck
|
|
0.020 |
GeneticVariation |
BEFREE |
MTHFD1 G1958A, BHMT G742A, TC2 C776G and TC2 A67G polymorphisms and head and neck squamous cell carcinoma risk.
|
21630102 |
2012 |
|
rs3733890
|
BHMT;DMGDH
|
Breast Carcinoma
|
|
0.020 |
GeneticVariation |
BEFREE |
The betaine-homocysteine methyltransferase gene (BHMT) rs3733890 polymorphism was associated with reduced breast cancer-specific mortality (hazard ratio, 0.64; 95% confidence interval, 0.42-0.97).
|
19635752 |
2009 |
|
rs3733890
|
BHMT;DMGDH
|
Malignant neoplasm of breast
|
|
0.020 |
GeneticVariation |
BEFREE |
The betaine-homocysteine methyltransferase gene (BHMT) rs3733890 polymorphism was associated with reduced breast cancer-specific mortality (hazard ratio, 0.64; 95% confidence interval, 0.42-0.97).
|
19635752 |
2009 |
|
rs3733890
|
BHMT;DMGDH
|
Spina Bifida
|
|
0.020 |
GeneticVariation |
BEFREE |
With respect to spina bifida, we observed ORs with 95% confidence intervals that did not include 1.0 for the following SNPs (heterozygous or homozygous) relative to the reference genotype: BHMT (rs3733890) OR = 1.8 (1.1-3.1), CBS (rs2851391) OR = 2.0 (1.2-3.1); CBS (rs234713) OR = 2.9 (1.3-6.7); MTHFD1 (rs2236224) OR = 1.7 (1.1-2.7); MTHFD1 (hcv11462908) OR = 0.2 (0-0.9); MTHFD2 (rs702465) OR = 0.6 (0.4-0.9); MTHFD2 (rs7571842) OR = 0.6 (0.4-0.9); MTHFR (rs1801133) OR = 2.0 (1.2-3.1); MTRR (rs162036) OR = 3.0 (1.5-5.9); MTRR (rs10380) OR = 3.4 (1.6-7.1); MTRR (rs1801394) OR = 0.7 (0.5-0.9); MTRR (rs9332) OR = 2.7 (1.3-5.3); TYMS (rs2847149) OR = 2.2 (1.4-3.5); TYMS (rs1001761) OR = 2.4 (1.5-3.8); and TYMS (rs502396) OR = 2.1 (1.3-3.3).
|
19493349 |
2009 |
|
rs3733890
|
BHMT;DMGDH
|
Breast Carcinoma
|
|
0.020 |
GeneticVariation |
BEFREE |
The BHMT rs3733890 polymorphism was also examined but was found not to be associated with breast cancer risk.
|
18230680 |
2008 |
|
rs3733890
|
BHMT;DMGDH
|
Malignant neoplasm of breast
|
|
0.020 |
GeneticVariation |
BEFREE |
The BHMT rs3733890 polymorphism was also examined but was found not to be associated with breast cancer risk.
|
18230680 |
2008 |
|
rs3733890
|
BHMT;DMGDH
|
Spina Bifida
|
|
0.020 |
GeneticVariation |
BEFREE |
The results of this study indicated that individuals homozygous for the single nucleotide polymorphism R239Q in BHMT did not have elevated risks for spina bifida.
|
15887275 |
2005 |
|
rs3733890
|
BHMT;DMGDH
|
Attention deficit hyperactivity disorder
|
|
0.010 |
GeneticVariation |
BEFREE |
MTHFR rs1801131, MTR rs1805087 and BHMT rs3733890 also showed association with ADHD index.
|
29407547 |
2018 |
|
rs3733890
|
BHMT;DMGDH
|
Childhood Acute Lymphoblastic Leukemia
|
|
0.010 |
GeneticVariation |
BEFREE |
BHMT (rs3733890) polymorphism showed no association with ALL.
|
28582843 |
2017 |
|
rs3733890
|
BHMT;DMGDH
|
Complete Trisomy 21 Syndrome
|
|
0.010 |
GeneticVariation |
BEFREE |
In the present case-control association study, we investigated the relationship of three single-nucleotide polymorphisms (SNPs) (phosphatidylethanolamine N-methyltransferase (PEMT) rs12325817, choline dehydrogenase (CHDH) rs12676 and homocysteine methyltransferase (BHMT) rs3733890) of choline metabolism with risk for DS.
|
27677362 |
2017 |
|
rs3733890
|
BHMT;DMGDH
|
Down Syndrome
|
|
0.010 |
GeneticVariation |
BEFREE |
In the present case-control association study, we investigated the relationship of three single-nucleotide polymorphisms (SNPs) (phosphatidylethanolamine N-methyltransferase (PEMT) rs12325817, choline dehydrogenase (CHDH) rs12676 and homocysteine methyltransferase (BHMT) rs3733890) of choline metabolism with risk for DS.
|
27677362 |
2017 |
|
rs3733890
|
BHMT;DMGDH
|
Acute lymphocytic leukemia
|
|
0.010 |
GeneticVariation |
BEFREE |
BHMT (rs3733890) polymorphism showed no association with ALL.
|
28582843 |
2017 |